Pharmspective Publishes White Paper: Health Care Reform and the Reshaping of the Pharmaceutical Selling Model

How the Value of Pharmaceuticals Will be Redefined in 2014

Mar 08, 2012, 07:07 ET from Pharmspective, LLC

NEW YORK, March 8, 2012 /PRNewswire/ -- Pharmspective, LLC today released the white paper, Health Care Reform and the Reshaping of the Pharmaceutical Selling Model, forecasting how health care reform will redefine the marketing & sales landscape of the pharmaceutical industry and transform customer relationships. 

The Pharmspective white paper will cover the impact of healthcare reform changes on physicians, hospitals, payers, and employers and offer a window into how these changes will influence the roles of pharmaceutical field sales representatives, account managers, reimbursement specialists, hospital representatives, and customer marketing groups.  The paper will also include a discussion of:

  • The influence of State Exchanges and Medicare ACOs, post-2014
  • The impact of employer decisions on  access and coverage
  • The environment facing physicians as new payer entities and third-party administrators emerge

"This legislation will require pharmaceutical manufacturers to build the rationale for therapy adoption across a broader set of decision influencers. In all cases, selling will require greater knowledge of the customer's reimbursement structure, business model, and incentives," says Stephen Reid, Managing Partner & Co-Founder of Pharmspective, LLC.

To learn more about how companies can navigate through the 400-plus key provisions of the healthcare reform legislation, click here to read the full report:

Pharmspective recently published another white paper, Decision Visualization: Making Pharma Market Research More Relevant in a New Era, reporting on the new evolving decision-making process of prescribers of specialty therapeutics, also available at:

About Pharmspective: Pharmspective, LLC ( is a Specialty Therapeutics market research firm providing commercial insights and knowledge management applications for the biopharmaceutical industry. The company is uniquely focused on understanding the buying process for specialty therapeutics through syndicated market research studies examining clinical decision-making, drug acquisition, access and reimbursement, and patient administration for specialty therapeutics in autoimmune diseases (rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn's/UC, lupus) and oncology. Pharmspective's proprietary knowledge management applications create a superior user experience that broadens client understanding of and perspective on research findings. Pharmspective™ is a trademark of Pharmspective LLC. Follow Pharmspective on The company maintains offices in New York City and St. Louis, MO.

Contact:  Jennifer Strathmann,
314-814-2729 x1002

SOURCE Pharmspective, LLC